Table 1.
Demographic characteristics and CBC among the studied groups.
| Characteristics of groups | Mean ± SD | Median (range) | Test of significance and P value | Post hoc P value |
|---|---|---|---|---|
| Age (year) | P1 = 0.07 | |||
| Valproate-treated patients | 3.4 ± 2.6 | 2 (0.92–8) | Kruskal–Wallis test = 5.45 | P2 = 0.33 |
| Levatiracetam-treated patients | 4.2 ± 2.1 | 5 (1–8) | P value = 0.14 | P3 = 0.15 |
| Multidrug-treated patients | 3.4 ± 1.6 | 4 (1–6) | P4 = 0.05 | |
| Controls | 3.9 ± 2.3 | 3 (1–8) | P5 = 0.83 | |
| P6 = 0.63 | ||||
| Sex | Male | Female | P1 = 0.16 | |
| Valproate-treated patients | 36 (67.9%) | 17 (32.1%) | χ2 test = 2.35 | P2 = 0.84 |
| Levatiracetam-treated patients | 29 (54.7%) | 24 (45.3%) | P value = 0.50 | P3 = 0.68 |
| Multidrug-treated patients | 35 (66.0%) | 18 (34.0%) | P4 = 0.23 | |
| Controls | 34 (64.2%) | 19 (35.8%) | P5 = 0.32 | |
| P6 = 0.84 | ||||
| Hemoglobin (g/dl) | P1 = 0.95 | |||
| Valproate-treated patients | 11.9 ± 0.78 | 12 (10–12.8) | ANOVA test = 1.15 | P2 = 0.11 |
| Levatiracetam-treated patients | 11.9 ± 1.3 | 11.8 (10.2–16) | P value = 0.33 | P3 = 0.45 |
| Multidrug-treated patients | 11.6 ± 0.65 | 11.5 (10.8–12.6) | P4 = 0.12 | |
| Controls | 11.8 ± 0.47 | 11.8 (11–13) | P5 = 0.49 | |
| P6 = 0.39 | ||||
| White blood cells (×103/mm3) | P1 < 0.001** | |||
| Valproate-treated patients | 6.5 ± 1.2 | 6.9 (5–8.1) | ANOVA test = 11.41 | P2 = 0.02* |
| Levatiracetam-treated patients | 8.2 ± 1.9 | 7.8 (5.7–11.5) | P value < 0.001** | P3 < 0.001** |
| Multidrug-treated patients | 7.3 ± 1.8 | 6.5 (5–10.5) | P4 = 0.006* | |
| Controls | 8.1 ± 1.9 | 8.5 (5–11.5) | P5 = 0.87 | |
| P6 = 0.01* | ||||
| Platelet (×103/mm3) | P1 = 0.30 | |||
| Valproate-treated patients | 263.4 ± 41.0 | 250 (213–355) | ANOVA test = 1.20 | P2 = 0.69 |
| Levatiracetam-treated patients | 273.9 ± 60.9 | 269 (198–452) | P value = 0.31 | P3 = 0.24 |
| Multidrug-treated patients | 259.3 ± 42.3 | 260 (187–319) | P4 = 0.15 | |
| Controls | 275.2 ± 59.9 | 267 (194–452) | P5 = 0.89 | |
| P6 = 0.12 |
P1: valproate-treated patients versus levatiracetam-treated patients; P2: valproate-treated patients versus multidrug-treated patients; P3: valproate-treated patients versus controls. P4: levatiracetam-treated patients versus multidrug-treated patients; P5: levatiracetam-treated patients versus controls; P6: multidrug-treated patients versus controls.
*Significant difference. **Highly significant difference.